Search

Your search keyword '"Alessi, F."' showing total 112 results
Start Over Author "Alessi, F."
112 results on '"Alessi, F."'

1. POS0767 CLINICAL AND SEROLOGICAL FEATURES OF PAEDIATRIC SJOGREN’S DISEASE AND COMPARISON WITH ADULT PATIENTS: A MULTICENTRE ITALIAN STUDY

Author

Riccio, F., primary, Ancona, S., additional, Gandolfo, S., additional, Pistorio, A., additional, Irace, R., additional, Alessi, F., additional, Alboreto, E., additional, Campus, S., additional, Marino, A., additional, Covizzi, C., additional, La Bella, S., additional, Manfrè, V., additional, Naddei, R., additional, Gattorno, M., additional, Ciccia, F., additional, and Malattia, C., additional

Published
2024
Full Text
View/download PDF

2. A Complete Characterization of Complete Intersection-Type Theories

Author

Dezani-Ciancaglini, M., Honsell, F., and Alessi, F.

Subjects
Computer Science - Logic in Computer Science, F.4.1, F.3.3, F.3.2, D.1.1
Abstract

We characterize those intersection-type theories which yield complete intersection-type assignment systems for lambda-calculi, with respect to the three canonical set-theoretical semantics for intersection-types: the inference semantics, the simple semantics and the F-semantics. These semantics arise by taking as interpretation of types subsets of applicative structures, as interpretation of the intersection constructor set-theoretic inclusion, and by taking the interpretation of the arrow constructor a' la Scott, with respect to either any possible functionality set, or the largest one, or the least one. These results strengthen and generalize significantly all earlier results in the literature, to our knowledge, in at least three respects. First of all the inference semantics had not been considered before. Secondly, the characterizations are all given just in terms of simple closure conditions on the preorder relation on the types, rather than on the typing judgments themselves. The task of checking the condition is made therefore considerably more tractable. Lastly, we do not restrict attention just to lambda-models, but to arbitrary applicative structures which admit an interpretation function. Thus we allow also for the treatment of models of restricted lambda-calculi. Nevertheless the characterizations we give can be tailored just to the case of lambda-models., Comment: 26 pages, no figure

Published
2000

6. Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19):relationship with mortality

Author

Violi, F., Ceccarelli, G., Cangemi, R., Cipollone, F., D'Ardes, D., Oliva, A., Pirro, M., Rocco, M., Alessandri, F., D'Ettorre, G., Lichtner, M., Pignatelli, P., Ferro, D., Ruberto, F., Lip, G. Y. H., Pugliese, F., Mastroianni, C. M., Albante, A., Auricchio, D., De Lazzaro, F., M. De Lauri D., Di Santo, C., Ianni, S., Magnanimi, E., Ratini, F., Sabani, A., Titi, L., Vaccaro, P., Giordano, G., Manganelli, C., Mancone, M., Bruno, K., Celli, P., Consolo, S., Croce, C., Giannetti, L., Martelli, S., Messina, T., Pattelli, E., Perrella, S., Portieri, M., Ricci, C., Almenrader, N., Arzilla, R., Delia, E., Di Giovanni, C., Laderchi, A., Macri, C., Marandola, M., Nardecchia, G., Pacilli, M., Pacini, F., Araimo Morselli, F., Imperiale, C., Tordiglione, P., Ciardi, M. R., Ajassa, C., D'Agostino, C., Russo, G., Trinchieri, V., Guariglia, P., Antonelli, L., Cuomo, R. M., Carnevalini, M., Mastropietro, C., Iaiani, G., Mezzaroma, I., Falciano, M., Brogi, A., Celani, L., Cavallari, N. E., Rivano Capparuccia, M., Massetti, A. P., Fimiani, C., Santori, M., Bianchi, A., Franchi, C., De Angelis, M., Sereno, S., Furlan, C., De Sanctis, G., Paoletti, F., Pasculli, P., Cogliati Dezza, F., Vassalini, P., Cancelli, F., De Girolamo, G., Savelloni, G., Valeri, S., Siccardi, G., Alessi, F., Recchia, G., Ridolfi, M., Romani, F. E., Aronica, R., Filippi, V., Vera, M., Volpicelli, L., Candy, M., Alban, R., Di Bari, S., Gavaruzzi, F., Casali, E., Carli, M. S., Zingaropoli, A. M., Perri, V., Santinelli, L., Pinacchio, C., Nijhawan, P., Miele, C. M., Innocenti, P. G., and Mengoni, F.

Subjects
Male, covid-19, mortality, sars-cov-2, thrombosis, Coronary Artery Disease, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, law.invention, Coronary artery disease, 0302 clinical medicine, law, 80 and over, Coronary Artery Disease/epidemiology, Odds Ratio, SARS-cov-2, 030212 general & internal medicine, Prospective Studies, Aged, 80 and over, Thromboembolism/epidemiology, biology, Hazard ratio, Middle Aged, Mortality/trends, Intensive care unit, Thrombosis, Venous thrombosis, Intensive Care Units, C-Reactive Protein, Emergency Medicine, Cardiology, COVID-19/complications, Female, medicine.medical_specialty, Fibrin Fibrinogen Degradation Products/analysis, Fibrin Fibrinogen Degradation Products, 03 medical and health sciences, C-Reactive Protein/analysis, Internal medicine, Thromboembolism, Internal Medicine, medicine, Humans, Mortality, Aged, Proportional Hazards Models, Intensive Care Units/organization & administration, business.industry, C-reactive protein, COVID-19, Odds ratio, medicine.disease, Im - Original, Logistic Models, Heart failure, biology.protein, business
Abstract

Background Patients with coronavirus disease 2019 (Covid-19) may experience venous thrombosis while data regarding arterial thrombosis are sparse. Methods Prospective multicenter study in 5 hospitals including 373 patients with Covid-19-related pneumonia. Demographic data, laboratory findings including coagulation tests and comorbidities were reported. During the follow-up any arterial or venous thrombotic events and death were registered. Results Among 373 patients, 75 (20%) had a thrombotic event and 75 (20%) died. Thrombotic events included 41 venous thromboembolism and 34 arterial thrombosis. Age, cardiovascular disease, intensive care unit treatment, white blood cells, D-dimer, albumin and troponin blood levels were associated with thrombotic events. In a multivariable regression logistic model, intensive care unit treatment (Odds Ratio [OR]: 6.0; 95% Confidence Interval [CI] 2.8–12.6; p p = 0.022); and albumin levels (OR: 0.49; 95% CI 0.28–0.87; p = 0.014) were associated with ischemic events. Age, sex, chronic obstructive pulmonary disease, diabetes, heart failure, coronary heart disease, intensive care unit treatment, in-hospital thrombotic events, D-dimer, C-reactive protein, troponin, and albumin levels were associated with mortality. A multivariable Cox regression analysis showed that in-hospital thrombotic events (hazard ratio [HR]: 2.72; 95% CI 1.59–4.65; p p = 0.001), and albumin (HR: 0.447; 95% CI 0.277–0.723; p = 0.001) predicted morality. Conclusions Covid-19 patients experience an equipollent rate of venous and arterial thrombotic events, that are associated with poor survival. Early identification and appropriate treatment of Covid-19 patients at risk of thrombosis may improve prognosis.

Published
2021

7. Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)

Author

Maddaloni, E., D'Onofrio, L., Alessandri, F., Mignogna, C., Leto, G., Pascarella, G., Mezzaroma, I., Lichtner, M., Pozzilli, P., Agro, F. E., Rocco, M., Pugliese, F., Lenzi, A., Holman, R. R., Mastroianni, C. M., Buzzetti, R., Ajassa, C., Alban, R., Alessi, F., Aronica, R., Belvisi, V., Candy, M., Caputi, A., Carrara, A., Casali, E., Cavallari, E. N., Ceccarelli, G., Celani, L., Ciardi, M. R., Coraggio, L., Curtolo, A., D'Agostino, C., D'Ettorre, G., De Giorgi, F., De Girolamo, G., Filippi, V., Gnessi, L., Luordi, C., Moretti, C., Recchia, G., Ridolfi, M., Romani, F. E., Russo, G., Ruberto, F., Savelloni, G., Siccardi, G., Siena, A., Sterpetti, S., Valeri, S., Vera, M., Volpicelli, L., Watanabe, M., Aiuti, M., Campagna, G., Del Borgo, C., Fondaco, L., Kertusha, B., Leonetti, F., Marocco, R., Masala, R., Zuccala, P., Nonnis, G., Rigoli, A., Strumia, A., and Alampi, D.

Subjects
lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, multimorbidity, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Pneumonia, Viral, pandemics, Logistic regression, metabolic diseases, law.invention, coronavirus infections, male, law, Diabetes mellitus, Internal medicine, middle aged, medicine, 80 and over, copd, covid-19, diabetes, hypertension, sars-cov-2, aged, cardiovascular diseases, diabetes mellitus, female, follow-up studies, humans, pneumonia, viral, prognosis, retrospective studies, risk factors, betacoronavirus, COPD, Original Investigation, Aged, 80 and over, Mechanical ventilation, business.industry, SARS-CoV-2, Confounding, Diabetes, Retrospective cohort study, Odds ratio, medicine.disease, Intensive care unit, lcsh:RC666-701, Hypertension, Cardiology and Cardiovascular Medicine, business, Covid-19
Abstract

Background Cardiometabolic disorders may worsen Covid-19 outcomes. We investigated features and Covid-19 outcomes for patients with or without diabetes, and with or without cardiometabolic multimorbidity. Methods We collected and compared data retrospectively from patients hospitalized for Covid-19 with and without diabetes, and with and without cardiometabolic multimorbidity (defined as ≥ two of three risk factors of diabetes, hypertension or dyslipidaemia). Multivariate logistic regression was used to assess the risk of the primary composite outcome (any of mechanical ventilation, admission to an intensive care unit [ICU] or death) in patients with diabetes and in those with cardiometabolic multimorbidity, adjusting for confounders. Results Of 354 patients enrolled, those with diabetes (n = 81), compared with those without diabetes (n = 273), had characteristics associated with the primary composite outcome that included older age, higher prevalence of hypertension and chronic obstructive pulmonary disease (COPD), higher levels of inflammatory markers and a lower PaO2/FIO2 ratio. The risk of the primary composite outcome in the 277 patients who completed the study as of May 15th, 2020, was higher in those with diabetes (Adjusted Odds Ratio (adjOR) 2.04, 95%CI 1.12–3.73, p = 0.020), hypertension (adjOR 2.31, 95%CI: 1.37–3.92, p = 0.002) and COPD (adjOR 2.67, 95%CI 1.23–5.80, p = 0.013). Patients with cardiometabolic multimorbidity were at higher risk compared to patients with no cardiometabolic conditions (adjOR 3.19 95%CI 1.61–6.34, p = 0.001). The risk for patients with a single cardiometabolic risk factor did not differ with that for patients with no cardiometabolic risk factors (adjOR 1.66, 0.90–3.06, adjp = 0.10). Conclusions Patients with diabetes hospitalized for Covid-19 present with high-risk features. They are at increased risk of adverse outcomes, likely because diabetes clusters with other cardiometabolic conditions.

Published
2020

8. LF+ in Coq for fast-and-loose reasoning

Author

Alessi, F, Ciaffaglione, A, Di Gianantonio, P, Honsell, F, Lenisa, M, and Scagnetto, I

Subjects
Logical Frameworks, Logical Frameworks, Type Theory, Formal Reasoning, Type Theory, Formal Reasoning
Published
2019

15. CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice

Author

Poggi, M, Morin, M, Bastelica, D, Govers, R, Canault, M, Bernot, D, Georgelin, O, Verdier, M, Burcelin, R, Olive, D, Alessi, Marie-Christine, Peiretti, F, Nunès, J A, Poggi, F, Morin, Fanny, Bastelica, F, Govers, F, Canault, F, Bernot, F, Georgelin, F, Verdier, François, Burcelin, F, Olive, F, Alessi, F, Nutrition, obésité et risque thrombotique (NORT), Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche sur l'Enseignement et l'Apprentissage des Sciences (CREAS), Université de Sherbrooke [Sherbrooke], Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU), Génie des procédés frigorifiques (UR GPAN), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratory of Phytopathology, Wageningen University and Research Centre [Wageningen] (WUR), Francecol Technology, EA 4279 Laboratoire Physiologie des Fruits et Légumes, Avignon Université (AU), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Sherbrooke (UdeS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Wageningen University and Research [Wageningen] (WUR), Societe Francophone du Diabete, European society of cardiology, Comite du Var de la Ligue contre le cancer, Fondation pour la Recherche Medicale [Equipe FRM DEQ20140329534], Aix-Marseille Universite, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Université de la Méditerranée - Aix-Marseille 2 - Institut National de la Recherche Agronomique (INRA) - Aix Marseille Université (AMU) - Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Institut Paoli-Calmettes - Aix Marseille Université (AMU), and Université Paul Sabatier - Toulouse 3 (UPS) - Hôpital de Rangueil - Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, MESH: Inflammation, MESH: Antigens, CD28, Endocrinology, Diabetes and Metabolism, MESH: Antigens, CD27, Medicine (miscellaneous), Adipose tissue, [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], MESH: Mice, Knockout, Mice, MESH: Obesity, MESH: Animals, MESH: Fatty Liver, ComputingMilieux_MISCELLANEOUS, MESH: Lipid Metabolism, Mice, Knockout, Nutrition and Dietetics, biology, Chemistry, Intracellular Signaling Peptides and Proteins, CD28, 3. Good health, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], MESH: Insulin Resistance, Adipose Tissue, Liver, medicine.symptom, MESH: Adipose Tissue, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Inflammation, chemical and pharmacologic phenomena, Proinflammatory cytokine, Insulin resistance, CD28 Antigens, MESH: Mice, Inbred C57BL, Internal medicine, MESH: Intracellular Signaling Peptides and Proteins, medicine, Animals, Obesity, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], MESH: Mice, Adiponectin, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Lipid Metabolism, medicine.disease, MESH: Male, Tumor Necrosis Factor Receptor Superfamily, Member 7, Fatty Liver, Mice, Inbred C57BL, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Disease Models, Animal, Endocrinology, MESH: Gene Deletion, biology.protein, Insulin Resistance, Steatosis, MESH: Disease Models, Animal, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Gene Deletion, GLUT4, MESH: Liver
Abstract

International audience; Lymphocytes have a critical role in visceral adipose tissue (AT) inflammation. The CD28 costimulatory molecule is required for lymphocyte activation and for the development of a functional regulatory T cells (Tregs) compartment; however, its role during obesity is unknown.During diet-induced obesity, we investigated the effects of selective interference with CD28 signaling using knockout mice (Cd28KO) and a CTLA4-Ig fusion protein inhibiting CD28-B7 interactions.Cd28 deficiency decreased pathogenic T cells and Treg content within AT without changing the macrophages number. Cd28KO epididymal but not subcutaneous fat was characterized by enlarged adipocytes, reduced levels of inflammatory cytokines and increased Glut4, adiponectin and lipogenic enzyme mRNA levels. This was associated with reduced inflammation, fat accumulation and enhanced glucose metabolism in liver. Weight gain and fasting glucose tolerance were not affected. CTLA4-Ig injections reduced the number of T cells in epididymal AT (epiAT) but not the inflammatory cytokines levels and failed to improve liver fat accumulation.Deletion of CD28 creates a new pro/anti-inflammatory balance in epiAT and liver and exerts a protective effect against hepatic steatosis.

Published
2015

16. First observation of the decay B0sbar -> D0K∗0 and a measurement of the ratio of branching fractions B(B0sbar -> D0K∗0) / B(B0sbar -> D0 rho0)

Author

Aaij, R, Abelian Beteta, C, Adeva, B, Adinolfi, M, Adrover, C, Affolder, A, Ajaltouni, Z, Albrecht, J, Alessi, F, Alexander, M, Alkhazov, G, Alvarez Cartelle, P, Alves, A, Amato, S, Amhis, Y, Anderson, J, Appleby, R, Gutierrez, O, Archilli, F, Arrabito, L, Artamonov, A, Artuso, M, Aslanides, E, Auriemma, G, Bachmann, S, Back, J, Bailey, D, Balagura, V, Baldini, W, Barlow, R, Barsche, C, Barsuk, S, Barter, W, Bates, A, Bauer, C, Bauer, T, Bay, A, Bediaga, I, Belous, K, Belyaev, I, Ben Haim, E, Benayoun, M, Bencivenni, G, Benson, S, Benton, J, Bernet, R, Bettler, M, van Beuzekom, M, Bien, A, Bifani, S, Bizzeti, A, Bjornstad, P, Blake, T, Blanc, F, Blanks, C, Blouw, J, Blusk, S, Bobrov, A, Bocci, V, Bondar, A, Bondar, N, Bonivento, W, Borghi, S, Borgia, A, Bowcock, T, Bozzi, C, Brambach, T, van den Brand, J, Bressieux, J, Brett, D, Brisbane, S, Britschl, M, Britton, T, Brook, N, Brown, H, Buechler Germann, A, Burducea, I, Bursche, A, Buytaert, J, Cadeddu, S, Carvajal, J, Callot, O, Calvo Gomez, M, Camboni, A, Campana, R, Carbone, A, Carboni, G, Cardinale, R, Cardini, A, Carson, L, Akiba, K, Casse, G, Cattaneo, M, Charles, M, Charpentier, P, Chiapolini, N, Ciba, K, Cid Vidal, X, Ciezarek, G, Clarke, P, Clemencic, M, Cliff, H, Closier, J, Coca, C, Coco, V, Cogan, J, Collins, P, Comerma Montells, A, Constantin, F, Conti, G, Contu, A, Cook, A, Coombes, M, Corti, G, Cowan, G, Currie, R, D'Almagne, B, D'Ambrosio, C, David, P, De Bonis, I, De Capua, S, De Cian, M, De Lorenzi, F, De Miranda, J, De Paula, L, De Simone, P, Decamp, D, Deckenhoff, M, Degaudenzi, H, Deissenroth, M, Del Buono, L, Deplano, C, Deschamps, O, Dettori, F, Dickens, J, Dijkstra, H, Diniz Batista, P, Domingo Bonal, F, Donleavy, S, Dosil Suarez, A, Dossett, D, Dovbnya, A, Dupertuis, F, Dzhelyadin, R, Easo, S, Egede, U, Egorychev, V, Eidelman, S, van Eijk, D, Eisele, F, Eisenhardt, S, Ekelhof, R, Eklund, L, Elsasser, C, d'Enterria, D, Esperante Pereira, D, Esteve, L, Falabella, A, Faerber, C, Fardell, G, Farinelli, C, Farry, S, Fave, V, Fernandez Albor, V, Ferro Luzzi, M, Filippov, S, Fitzpatrick, C, Fontana, M, Fontanelli, F, Forty, R, Frank, M, Frei, C, Frosini, M, Furcas, S, Gallas Torreira, A, Galli, D, Gandelman, M, Gandini, P, Gao, Y, Garnier, J, Garofoli, J, Tico, J, Garrido, L, Gascon, D, Gaspar, C, Gauvin, N, Gersabeck, M, Gershon, T, Ghez, P, Gibson, V, Gligorov, V, Goebel, C, Golubkov, D, Golutvin, A, Gomes, A, Gordon, H, Grabalosa Gandara, M, Graciani Diaz, R, Cardoso, L, Grauges, E, Graziani, G, Grecu, A, Greening, E, Gregson, S, Gui, B, Gushchin, E, Guz, Y, Gys, T, Haefeli, G, Haen, C, Haines, S, Hampson, T, Hansmann Menzemer, S, Harji, R, Harnew, N, Harrison, J, Harrison, P, He, J, Heijne, V, Hennessy, K, Henrard, P, Hernando Morata, J, van Herwijnen, E, Hicks, E, Hofmann, W, Holubyev, K, Hopchev, P, Hulsbergen, W, Hunt, P, Huse, T, Huston, R, Hutchcroft, D, Hynds, D, Iakovenko, V, Ilten, P, Imong, J, Jacobsson, R, Jaeger, A, Hussein, M, Jans, E, Jansen, F, Jaton, P, Jean Marie, B, Jing, F, John, M, Johnson, D, Jones, C, Jost, B, Kandybei, S, Karacson, M, Karbach, T, Keaveney, J, Kerze, U, Ketel, T, Keune, A, Khanji, B, Kim, Y, Knecht, M, Koblitz, S, Koppenburg, P, Kozlinskiy, A, Kravchuk, L, Kreplin, K, Kreps, M, Krocker, G, Krokovny, P, Kruse, F, Kruzelecki, K, Kucharczyk, M, Kukulak, S, Kumar, R, Kvaratskheliya, T, La Thi, V, Lacarrere, D, Lafferty, G, Lai, A, Lambert, D, Lambert, R, Lanciotti, E, Lanfranchi, G, Langenbruch, C, Latham, T, Le Gac, R, van Leerdam, J, Lees, J, Lefevre, R, Leflat, A, Lefrancois, J, Leroy, O, Lesiak, T, Li, L, Gioi, L, Lieng, M, Liles, M, Lindner, R, Linn, C, Liu, B, Liu, G, Lopes, J, Lopez Asamar, E, Lopez March, N, Luisier, J, Machefert, F, Machikhiliyan, I, Maciuc, F, Maev, O, Magnin, J, Malde, S, Mamunur, R, Manca, G, Mancinelli, G, Mangiafave, N, Marconi, U, Maerki, R, Marks, J, Martellotti, G, Martens, A, Martin, L, Sanchez, A, Santos, D, Massafferri, A, Mathe, Z, Matteuzzi, C, Matveev, M, Maurice, E, Maynard, B, Mazurov, A, McGregor, G, McNulty, R, Mclean, C, Meissner, M, Merk, M, Merkel, J, Messi, R, Miglioranzi, S, Milanes, D, Minard, M, Monteil, S, Moran, D, Morawski, P, Mountain, R, Mous, I, Muheim, F, Mueller, K, Muresan, R, Muryn, B, Musy, M, Mylroie Smith, J, Naik, P, Nakada, T, Nandakumar, R, Nardulli, J, Nasteva, I, Nedos, M, Needham, M, Neufeld, N, Nguyen Mau, C, Nicol, M, Nies, S, Niess, V, Nikitin, N, Nomerotski, A, Oblakowska Mucha, A, Obraztsov, V, Oggero, S, Ogilvy, S, Okhrimenko, O, Oldeman, R, Orlandea, M, Otalora Goicochea, J, Owen, P, Pal, K, Palacios, J, Palano, A, Palutan, M, Panman, J, Papanestis, A, Pappagallo, M, Parkes, C, Parkinson, C, Passaleva, G, Patel, G, Patel, M, Paterson, S, Patrick, G, Patrignani, C, Pavel Nicorescu, C, Pazos Alvarez, A, Pellegrino, A, Penso, G, Altarelli, M, Perazzini, S, Perego, D, Perez Trigo, E, Perez Calero Yzquierdo, A, Perret, P, Perrin Terrin, M, Pessina, G, Petrella, A, Petrolini, A, Picatoste Olloqui, E, Pie Valls, B, Pietrzyk, B, Pilar, T, Pinci, D, Plackett, R, Playfer, S, Plo Casasus, M, Polok, G, Poluektov, A, Polycarpo, E, Popov, D, Popovici, B, Potterat, C, Powell, A, du Pree, T, Prisciandaro, J, Pugatch, V, Puig Navarro, A, Qian, W, Rademacker, J, Rakotomiaramanana, B, Range, M, Raniuk, I, Raven, G, Redford, S, Reid, M, dos Reis, A, Ricciardi, S, Rinnert, K, Romero, D, Robbe, P, Rodrigues, E, Rodrigues, F, Rodriguez Perez, P, Rogers, G, Roiser, S, Romanovsky, V, Rosello, M, Rouvinet, J, Ruf, T, Ruiz, H, Sabatino, G, Saborido Silva, J, Sagidova, N, Sail, P, Saitta, B, Salzmann, C, Sannino, M, Santacesaria, R, Santinelli, R, Santovetti, E, Sapunov, M, Sarti, A, Satriano, C, Satta, A, Savrie, M, Savrina, D, Schaack, R, Schiller, M, Schleich, S, Schmelling, M, Schmidt, B, Schneider, O, Schopper, A, Schune, M, Schwemmer, R, Sciascia, B, Sciubba, A, Seco, M, Semennikov, A, Senderowska, K, Sepp, I, Serra, N, Serrano, J, Seyfert, R, Shao, B, Shapkin, M, Shapoval, I, Shatalov, P, Shcheglov, Y, Shears, T, Shekhtman, L, Shevchenko, O, Shevchenko, V, Shires, A, Silva Coutinho, R, Skottowe, H, Skwarnicki, T, Smith, A, Smith, N, Smith, E, Sobczak, K, Soler, F, Solomin, A, Soomro, F, Souza De Paula, B, Spaan, B, Sparkes, A, Spradlin, P, Stagni, F, Stahl, S, Steinkamp, O, Stoica, S, Stone, S, Storaci, B, Straticiuc, M, Straumann, U, Styles, N, Subbiah, V, Swientek, S, Szczekowski, M, Szczypka, P, Szumlak, T, TJampens, S, Teodorescu, E, Teubert, F, Thomas, C, Thomas, E, van Tilburg, J, Tisserand, V, Tobin, M, Topp Joergensen, S, Torr, N, Tran, M, Tsaregorodtsev, A, Tuning, N, Ukleja, A, Urquijo, P, Uwer, U, Vagnoni, V, Valenti, G, Vazquez Gomez, R, Vazquez Regueiro, P, Vecchi, S, Velthuis, J, Veltri, M, Vervink, K, Viaud, B, Videau, I, Vilasis Cardona, X, Visniakov, J, Vollhardt, A, Voong, D, Vorobyev, A, Voss, H, Wacker, K, Wandernoth, S, Wang, J, Ward, D, Webber, A, Websdale, D, Whitehead, M, Wiedner, D, Wiggers, L, Wilkinson, G, Williams, M, Wilson, F, Wishahi, J, Witek, M, Witzeling, W, Wotton, S, Wyllie, K, Xie, Y, Xing, F, Xing, Z, Yang, Z, Young, R, Yushchenko, O, Zavertyaev, M, Zhang, L, Zhang, W, Zhang, Y, Zhelezov, A, Zhong, L, Zverev, E, Zvyagin, A., CALVI, MARTA, FANCHINI, ERICA, Aaij, R, Abelian Beteta, C, Adeva, B, Adinolfi, M, Adrover, C, Affolder, A, Ajaltouni, Z, Albrecht, J, Alessi, F, Alexander, M, Alkhazov, G, Alvarez Cartelle, P, Alves, A, Amato, S, Amhis, Y, Anderson, J, Appleby, R, Gutierrez, O, Archilli, F, Arrabito, L, Artamonov, A, Artuso, M, Aslanides, E, Auriemma, G, Bachmann, S, Back, J, Bailey, D, Balagura, V, Baldini, W, Barlow, R, Barsche, C, Barsuk, S, Barter, W, Bates, A, Bauer, C, Bauer, T, Bay, A, Bediaga, I, Belous, K, Belyaev, I, Ben Haim, E, Benayoun, M, Bencivenni, G, Benson, S, Benton, J, Bernet, R, Bettler, M, van Beuzekom, M, Bien, A, Bifani, S, Bizzeti, A, Bjornstad, P, Blake, T, Blanc, F, Blanks, C, Blouw, J, Blusk, S, Bobrov, A, Bocci, V, Bondar, A, Bondar, N, Bonivento, W, Borghi, S, Borgia, A, Bowcock, T, Bozzi, C, Brambach, T, van den Brand, J, Bressieux, J, Brett, D, Brisbane, S, Britschl, M, Britton, T, Brook, N, Brown, H, Buechler Germann, A, Burducea, I, Bursche, A, Buytaert, J, Cadeddu, S, Carvajal, J, Callot, O, Calvi, M, Calvo Gomez, M, Camboni, A, Campana, R, Carbone, A, Carboni, G, Cardinale, R, Cardini, A, Carson, L, Akiba, K, Casse, G, Cattaneo, M, Charles, M, Charpentier, P, Chiapolini, N, Ciba, K, Cid Vidal, X, Ciezarek, G, Clarke, P, Clemencic, M, Cliff, H, Closier, J, Coca, C, Coco, V, Cogan, J, Collins, P, Comerma Montells, A, Constantin, F, Conti, G, Contu, A, Cook, A, Coombes, M, Corti, G, Cowan, G, Currie, R, D'Almagne, B, D'Ambrosio, C, David, P, De Bonis, I, De Capua, S, De Cian, M, De Lorenzi, F, De Miranda, J, De Paula, L, De Simone, P, Decamp, D, Deckenhoff, M, Degaudenzi, H, Deissenroth, M, Del Buono, L, Deplano, C, Deschamps, O, Dettori, F, Dickens, J, Dijkstra, H, Diniz Batista, P, Domingo Bonal, F, Donleavy, S, Dosil Suarez, A, Dossett, D, Dovbnya, A, Dupertuis, F, Dzhelyadin, R, Easo, S, Egede, U, Egorychev, V, Eidelman, S, van Eijk, D, Eisele, F, Eisenhardt, S, Ekelhof, R, Eklund, L, Elsasser, C, D'Enterria, D, Esperante Pereira, D, Esteve, L, Falabella, A, Fanchini, E, Faerber, C, Fardell, G, Farinelli, C, Farry, S, Fave, V, Fernandez Albor, V, Ferro Luzzi, M, Filippov, S, Fitzpatrick, C, Fontana, M, Fontanelli, F, Forty, R, Frank, M, Frei, C, Frosini, M, Furcas, S, Gallas Torreira, A, Galli, D, Gandelman, M, Gandini, P, Gao, Y, Garnier, J, Garofoli, J, Tico, J, Garrido, L, Gascon, D, Gaspar, C, Gauvin, N, Gersabeck, M, Gershon, T, Ghez, P, Gibson, V, Gligorov, V, Goebel, C, Golubkov, D, Golutvin, A, Gomes, A, Gordon, H, Grabalosa Gandara, M, Graciani Diaz, R, Cardoso, L, Grauges, E, Graziani, G, Grecu, A, Greening, E, Gregson, S, Gui, B, Gushchin, E, Guz, Y, Gys, T, Haefeli, G, Haen, C, Haines, S, Hampson, T, Hansmann Menzemer, S, Harji, R, Harnew, N, Harrison, J, Harrison, P, He, J, Heijne, V, Hennessy, K, Henrard, P, Hernando Morata, J, van Herwijnen, E, Hicks, E, Hofmann, W, Holubyev, K, Hopchev, P, Hulsbergen, W, Hunt, P, Huse, T, Huston, R, Hutchcroft, D, Hynds, D, Iakovenko, V, Ilten, P, Imong, J, Jacobsson, R, Jaeger, A, Hussein, M, Jans, E, Jansen, F, Jaton, P, Jean Marie, B, Jing, F, John, M, Johnson, D, Jones, C, Jost, B, Kandybei, S, Karacson, M, Karbach, T, Keaveney, J, Kerze, U, Ketel, T, Keune, A, Khanji, B, Kim, Y, Knecht, M, Koblitz, S, Koppenburg, P, Kozlinskiy, A, Kravchuk, L, Kreplin, K, Kreps, M, Krocker, G, Krokovny, P, Kruse, F, Kruzelecki, K, Kucharczyk, M, Kukulak, S, Kumar, R, Kvaratskheliya, T, La Thi, V, Lacarrere, D, Lafferty, G, Lai, A, Lambert, D, Lambert, R, Lanciotti, E, Lanfranchi, G, Langenbruch, C, Latham, T, Le Gac, R, van Leerdam, J, Lees, J, Lefevre, R, Leflat, A, Lefrancois, J, Leroy, O, Lesiak, T, Li, L, Gioi, L, Lieng, M, Liles, M, Lindner, R, Linn, C, Liu, B, Liu, G, Lopes, J, Lopez Asamar, E, Lopez March, N, Luisier, J, Machefert, F, Machikhiliyan, I, Maciuc, F, Maev, O, Magnin, J, Malde, S, Mamunur, R, Manca, G, Mancinelli, G, Mangiafave, N, Marconi, U, Maerki, R, Marks, J, Martellotti, G, Martens, A, Martin, L, Sanchez, A, Santos, D, Massafferri, A, Mathe, Z, Matteuzzi, C, Matveev, M, Maurice, E, Maynard, B, Mazurov, A, Mcgregor, G, Mcnulty, R, Mclean, C, Meissner, M, Merk, M, Merkel, J, Messi, R, Miglioranzi, S, Milanes, D, Minard, M, Monteil, S, Moran, D, Morawski, P, Mountain, R, Mous, I, Muheim, F, Mueller, K, Muresan, R, Muryn, B, Musy, M, Mylroie Smith, J, Naik, P, Nakada, T, Nandakumar, R, Nardulli, J, Nasteva, I, Nedos, M, Needham, M, Neufeld, N, Nguyen Mau, C, Nicol, M, Nies, S, Niess, V, Nikitin, N, Nomerotski, A, Oblakowska Mucha, A, Obraztsov, V, Oggero, S, Ogilvy, S, Okhrimenko, O, Oldeman, R, Orlandea, M, Otalora Goicochea, J, Owen, P, Pal, K, Palacios, J, Palano, A, Palutan, M, Panman, J, Papanestis, A, Pappagallo, M, Parkes, C, Parkinson, C, Passaleva, G, Patel, G, Patel, M, Paterson, S, Patrick, G, Patrignani, C, Pavel Nicorescu, C, Pazos Alvarez, A, Pellegrino, A, Penso, G, Altarelli, M, Perazzini, S, Perego, D, Perez Trigo, E, Perez Calero Yzquierdo, A, Perret, P, Perrin Terrin, M, Pessina, G, Petrella, A, Petrolini, A, Picatoste Olloqui, E, Pie Valls, B, Pietrzyk, B, Pilar, T, Pinci, D, Plackett, R, Playfer, S, Plo Casasus, M, Polok, G, Poluektov, A, Polycarpo, E, Popov, D, Popovici, B, Potterat, C, Powell, A, du Pree, T, Prisciandaro, J, Pugatch, V, Puig Navarro, A, Qian, W, Rademacker, J, Rakotomiaramanana, B, Range, M, Raniuk, I, Raven, G, Redford, S, Reid, M, dos Reis, A, Ricciardi, S, Rinnert, K, Romero, D, Robbe, P, Rodrigues, E, Rodrigues, F, Rodriguez Perez, P, Rogers, G, Roiser, S, Romanovsky, V, Rosello, M, Rouvinet, J, Ruf, T, Ruiz, H, Sabatino, G, Saborido Silva, J, Sagidova, N, Sail, P, Saitta, B, Salzmann, C, Sannino, M, Santacesaria, R, Santinelli, R, Santovetti, E, Sapunov, M, Sarti, A, Satriano, C, Satta, A, Savrie, M, Savrina, D, Schaack, R, Schiller, M, Schleich, S, Schmelling, M, Schmidt, B, Schneider, O, Schopper, A, Schune, M, Schwemmer, R, Sciascia, B, Sciubba, A, Seco, M, Semennikov, A, Senderowska, K, Sepp, I, Serra, N, Serrano, J, Seyfert, R, Shao, B, Shapkin, M, Shapoval, I, Shatalov, P, Shcheglov, Y, Shears, T, Shekhtman, L, Shevchenko, O, Shevchenko, V, Shires, A, Silva Coutinho, R, Skottowe, H, Skwarnicki, T, Smith, A, Smith, N, Smith, E, Sobczak, K, Soler, F, Solomin, A, Soomro, F, Souza De Paula, B, Spaan, B, Sparkes, A, Spradlin, P, Stagni, F, Stahl, S, Steinkamp, O, Stoica, S, Stone, S, Storaci, B, Straticiuc, M, Straumann, U, Styles, N, Subbiah, V, Swientek, S, Szczekowski, M, Szczypka, P, Szumlak, T, Tjampens, S, Teodorescu, E, Teubert, F, Thomas, C, Thomas, E, van Tilburg, J, Tisserand, V, Tobin, M, Topp Joergensen, S, Torr, N, Tran, M, Tsaregorodtsev, A, Tuning, N, Ukleja, A, Urquijo, P, Uwer, U, Vagnoni, V, Valenti, G, Vazquez Gomez, R, Vazquez Regueiro, P, Vecchi, S, Velthuis, J, Veltri, M, Vervink, K, Viaud, B, Videau, I, Vilasis Cardona, X, Visniakov, J, Vollhardt, A, Voong, D, Vorobyev, A, Voss, H, Wacker, K, Wandernoth, S, Wang, J, Ward, D, Webber, A, Websdale, D, Whitehead, M, Wiedner, D, Wiggers, L, Wilkinson, G, Williams, M, Wilson, F, Wishahi, J, Witek, M, Witzeling, W, Wotton, S, Wyllie, K, Xie, Y, Xing, F, Xing, Z, Yang, Z, Young, R, Yushchenko, O, Zavertyaev, M, Zhang, L, Zhang, W, Zhang, Y, Zhelezov, A, Zhong, L, Zverev, E, and Zvyagin, A

Subjects
flavor physic, B physic, branching fraction, CKM angle gamma, experimental results
Abstract

The first observation of the decay B0sbar -> D0K∗0 using pp data collected by the LHCb detector at a centre-of-mass energy of 7 TeV, corresponding to an integrated luminosity of 36 pb(-1), is reported. A signal of 34.4 +/- 6.8 events is obtained and the absence of signal is rejected with a statistical significance of more than nine standard deviations. The B0sbar -> D0K∗0 branching fraction is measured relative to that of B0sbar-> D0 rho0 : B(B0sbar -> D0K∗0) / B(B0sbar-> D0 rho0) = 1.48+/-0.34+/-0.15+/-0.12, where the first uncertainty is statistical, the second systematic and the third is due to the uncertainty on the ratio of the B-0 and B-s(0) hadronisation fractions. (C) 2011 CERN. Published by Elsevier B.V. All right reserved.

Published
2011

17. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study

Author

Bonfanti, P, Valsecchi, L, Parazzini, F, Carradori, S, Pusterla, L, Fortuna, P, Timillero, L, Alessi, F, Ghiselli, G, Gabbuti, A, Di Cintio, E, Martinelli, C, Faggion, I, Landonio, S, Quirino, T, Bonfanti P., Valsecchi L., Parazzini F., Carradori S., Pusterla L., Fortuna P., Timillero L., Alessi F., Ghiselli G., Gabbuti A., Di Cintio E., Martinelli C., Faggion I., Landonio S., Quirino T., Bonfanti, P, Valsecchi, L, Parazzini, F, Carradori, S, Pusterla, L, Fortuna, P, Timillero, L, Alessi, F, Ghiselli, G, Gabbuti, A, Di Cintio, E, Martinelli, C, Faggion, I, Landonio, S, Quirino, T, Bonfanti P., Valsecchi L., Parazzini F., Carradori S., Pusterla L., Fortuna P., Timillero L., Alessi F., Ghiselli G., Gabbuti A., Di Cintio E., Martinelli C., Faggion I., Landonio S., and Quirino T.

Abstract

Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Design: A prospective cohort, multicenter study on HIV-positive patients starting treatment with at least one PI. Setting: Ten departments of infectious diseases in Northern Italy. Patients: A total of 1207 patients who started PI therapy in September 1997 and were consecutively observed up to April 1999. Main Outcome Measures: Adverse reactions following initiation of PI therapy, and time to therapy discontinuation due to AE. Results: During the study period, 35.9% patients presented adverse reactions of any grade, whereas 9.7% presented at least one serious AE. After 12 months of treatment, the percentage of patients who had interrupted treatment was 36% of ritonavir- treated patients, 14.2% of those treated with indinavir, 13.6% of ritonavir- saquinavir hard gel capsules (HGC)-treated patients, and 8.5% and 2.1%, respectively, for those treated with nelfinavir and saquinavir HGC. Women and patients with hepatitis experienced a significantly greater number of adverse events compared with other categories. Gastrointestinal events were more frequently observed in patients treated with either ritonavir alone or in combination with saquinavir HGC, as well as in patients receiving nelfinavir, although in this group serious events were rare. Here again, neurologic, metabolic, and hepatic toxicity occurred more frequently in ritonavir and ritonavir-saquinavir HGC treated patients. Allergic reactions were more often observed in patients receiving nelfinavir. Indinavir-treated patients presented the highest incidence of renal toxicity. Conclusion: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment. Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.

Published
2000

18. Intersection Types

Author

Alessi, F., Barendregt, H., Dekkers, W., Dezani, Mariangiola, Honsell, F., Severi, P., and Statman, R.

Published
2013

19. First observation of the decay (B)over-bar(S)(0) -> (DK)-K-0*(0) and a measurement of the ratio of branching fractions B((B)over-bar(S)(0)->(DK)-K-0*(0))/B((B)over-bar(0)-> D-0 rho(0))

Author

Aaij, R., Abelian Beteta, C., Adeva, B., Adinolfi, M., Adrover, C., Affolder, A., Ajaltouni, Z., Albrecht, J., Alessi, F., Alexander, M., Alkhazov, G., Alvarez Cartelle, P., Alves, A. A., Amato, S., Amhis, Y., Anderson, J., Appleby, R. B., Gutierrez, O. Aquines, Archilli, F., Arrabito, L., Artamonov, A., Artuso, M., Aslanides, E., Auriemma, G., Bachmann, S., Back, J. J., Bailey, D. S., Balagura, V., Baldini, W., Barlow, R. J., Barsche, C., Barsuk, S., Barter, W., Bates, A., Bauer, C., Bauer, Th, Bay, A., Bediaga, I., Belous, K., Belyaev, I., Ben-Haim, E., Benayoun, M., Bencivenni, G., Benson, S., Benton, J., Bernet, R., Bettler, M. -O, van Beuzekom, M., Bien, A., Bifani, S., Bizzeti, A., Bjornstad, P. M., Blake, T., Blanc, F., Blanks, C., Blouw, J., Blusk, S., Bobrov, A., Bocci, V., Bondar, A., Bondar, N., Bonivento, W., Borghi, S., Borgia, A., Bowcock, T. J. V., Bozzi, C., Brambach, T., van den Brand, J., Bressieux, J., Brett, D., Brisbane, S., Britschl, M., Britton, T., Brook, N. H., Brown, H., Buechler-Germann, A., Burducea, I., Bursche, A., Buytaert, J., Cadeddu, S., Carvajal, J. M. Caicedo, Callot, O., Calvi, M., Calvo Gomez, M., Camboni, A., Campana, R., Carbone, A., Carboni, G., Cardinale, R., Cardini, A., Carson, L., Akiba, K. Carvalho, Casse, G., Cattaneo, M., Charles, M., Charpentier, Ph, Chiapolini, N., Ciba, K., Cid Vidal, X., Ciezarek, G., Clarke, P. E. L., Clemencic, M., Cliff, H. V., Closier, J., Coca, C., Coco, V., Cogan, J., Collins, P., Comerma-Montells, A., Constantin, F., Conti, G., Contu, A., Cook, A., Coombes, M., Corti, G., Cowan, G. A., Currie, R., D'Almagne, B., D'Ambrosio, C., David, P., De Bonis, I., De Capua, S., De Cian, M., De Lorenzi, F., De Miranda, J. M., De Paula, L., De Simone, P., Decamp, D., Deckenhoff, M., Degaudenzi, H., Deissenroth, M., Del Buono, L., Deplano, C., Deschamps, O., Dettori, F., Dickens, J., Dijkstra, H., Diniz Batista, P., Domingo Bonal, F., Donleavy, S., Dosil Suarez, A., Dossett, D., Dovbnya, A., Dupertuis, F., Dzhelyadin, R., Easo, S., Egede, U., Egorychev, V., Eidelman, S., van Eijk, D., Eisele, F., Eisenhardt, S., Ekelhof, R., Eklund, L., Elsasser, Ch, d'Enterria, D. G., Esperante Pereira, D., Esteve, L., Falabella, A., Fanchini, E., Faerber, C., Fardell, G., Farinelli, C., Farry, S., Fave, V., Fernandez Albor, V., Ferro-Luzzi, M., Filippov, S., Fitzpatrick, C., Fontana, M., Fontanelli, F., Forty, R., Frank, M., Frei, C., Frosini, M., Furcas, S., Gallas Torreira, A., Galli, D., Gandelman, M., Gandini, P., Gao, Y., Garnier, J. -C., Garofoli, J., Tico, J. Garra, Garrido, L., Gascon, D., Gaspar, C., Gauvin, N., Gersabeck, M., Gershon, T., Ghez, Ph, Gibson, V., Gligorov, V. V., Goebel, C., Golubkov, D., Golutvin, A., Gomes, A., Gordon, H., Grabalosa Gandara, M., Graciani Diaz, R., Cardoso, L. A. Granado, Grauges, E., Graziani, G., Grecu, A., Greening, E., Gregson, S., Gui, B., Gushchin, E., Guz, Yu, Gys, T., Haefeli, G., Haen, C., Haines, S. C., Hampson, T., Hansmann-Menzemer, S., Harji, R., Harnew, N., Harrison, J., Harrison, P. F., He, J., Heijne, V., Hennessy, K., Henrard, P., Hernando Morata, J. A., van Herwijnen, E., Hicks, E., Hofmann, W., Holubyev, K., Hopchev, P., Hulsbergen, W., Hunt, P., Huse, T., Huston, R. S., Hutchcroft, D., Hynds, D., Iakovenko, V., Ilten, P., Imong, J., Jacobsson, R., Jaeger, A., Hussein, M. Jahjah, Jans, E., Jansen, F., Jaton, P., Jean-Marie, B., Jing, F., John, M., Johnson, D., Jones, C. R., Jost, B., Kandybei, S., Karacson, M., Karbach, T. M., Keaveney, J., Kerze, U., Ketel, T., Keune, A., Khanji, B., Kim, Y. M., Knecht, M., Koblitz, S., Koppenburg, P., Kozlinskiy, A., Kravchuk, L., Kreplin, K., Kreps, M., Krocker, G., Krokovny, P., Kruse, F., Kruzelecki, K., Kucharczyk, M., Kukulak, S., Kumar, R., Kvaratskheliya, T., La Thi, V. N., Lacarrere, D., Lafferty, G., Lai, A., Lambert, D., Lambert, R. W., Lanciotti, E., Lanfranchi, G., Langenbruch, C., Latham, T., Le Gac, R., van Leerdam, J., Lees, J. -P., Lefevre, R., Leflat, A., Lefrancois, J., Leroy, O., Lesiak, T., Li, L., Gioi, L. Li, Lieng, M., Liles, M., Lindner, R., Linn, C., Liu, B., Liu, G., Lopes, J. H., Lopez Asamar, E., Lopez-March, N., Luisier, J., Machefert, F., Machikhiliyan, I. V., Maciuc, F., Maev, O., Magnin, J., Malde, S., Mamunur, R. M. D., Manca, G., Mancinelli, G., Mangiafave, N., Marconi, U., Maerki, R., Marks, J., Martellotti, G., Martens, A., Martin, L., Sanchez, A. Martin, Santos, D. Martinez, Massafferri, A., Mathe, Z., Matteuzzi, C., Matveev, M., Maurice, E., Maynard, B., Mazurov, A., McGregor, G., McNulty, R., Mclean, C., Meissner, M., Merk, M., Merkel, J., Messi, R., Miglioranzi, S., Milanes, D. A., Minard, M. -N., Monteil, S., Moran, D., Morawski, P., Mountain, R., Mous, I., Muheim, F., Mueller, K., Muresan, R., Muryn, B., Musy, M., Mylroie-Smith, J., Naik, P., Nakada, T., Nandakumar, R., Nardulli, J., Nasteva, I., Nedos, M., Needham, M., Neufeld, N., Nguyen-Mau, C., Nicol, M., Nies, S., Niess, V., Nikitin, N., Nomerotski, A., Oblakowska-Mucha, A., Obraztsov, V., Oggero, S., Ogilvy, S., Okhrimenko, O., Oldeman, R., Orlandea, M., Otalora Goicochea, J. M., Owen, P., Pal, K., Palacios, J., Palano, A., Palutan, M., Panman, J., Papanestis, A., Pappagallo, M., Parkes, C., Parkinson, C. J., Passaleva, G., Patel, G. D., Patel, M., Paterson, S. K., Patrick, G. N., Patrignani, C., Pavel-Nicorescu, C., Pazos Alvarez, A., Pellegrino, A., Penso, G., Altarelli, M. Pepe, Perazzini, S., Perego, D. L., Perez Trigo, E., Perez-Calero Yzquierdo, A., Perret, P., Perrin-Terrin, M., Pessina, G., Petrella, A., Petrolini, A., Picatoste Olloqui, E., Pie Valls, B., Pietrzyk, B., Pilar, T., Pinci, D., Plackett, R., Playfer, S., Plo Casasus, M., Polok, G., Poluektov, A., Polycarpo, E., Popov, D., Popovici, B., Potterat, C., Powell, A., du Pree, T., Prisciandaro, J., Pugatch, V., Puig Navarro, A., Qian, W., Rademacker, J. H., Rakotomiaramanana, B., Range, M. S., Raniuk, I., Raven, G., Redford, S., Reid, M. M., dos Reis, A. C., Ricciardi, S., Rinnert, K., Romero, D. A. Roa, Robbe, P., Rodrigues, E., Rodrigues, F., Rodriguez Perez, P., Rogers, G. J., Roiser, S., Romanovsky, V., Rosello, M., Rouvinet, J., Ruf, T., Ruiz, H., Sabatino, G., Saborido Silva, J. J., Sagidova, N., Sail, P., Saitta, B., Salzmann, C., Sannino, M., Santacesaria, R., Santinelli, R., Santovetti, E., Sapunov, M., Sarti, A., Satriano, C., Satta, A., Savrie, M., Savrina, D., Schaack, R., Schiller, M., Schleich, S., Schmelling, M., Schmidt, B., Schneider, O., Schopper, A., Schune, M. -H., Schwemmer, R., Sciascia, B., Sciubba, A., Seco, M., Semennikov, A., Senderowska, K., Sepp, I., Serra, N., Serrano, J., Seyfert, R., Shao, B., Shapkin, M., Shapoval, I., Shatalov, P., Shcheglov, Y., Shears, T., Shekhtman, L., Shevchenko, O., Shevchenko, V., Shires, A., Silva Coutinho, R., Skottowe, H. P., Skwarnicki, T., Smith, A. C., Smith, N. A., Smith, E., Sobczak, K., Soler, F. J. P., Solomin, A., Soomro, F., Souza De Paula, B., Spaan, B., Sparkes, A., Spradlin, P., Stagni, F., Stahl, S., Steinkamp, O., Stoica, S., Stone, S., Storaci, B., Straticiuc, M., Straumann, U., Styles, N., Subbiah, V. K., Swientek, S., Szczekowski, M., Szczypka, P., Szumlak, T., TJampens, S., Teodorescu, E., Teubert, F., Thomas, C., Thomas, E., van Tilburg, J., Tisserand, V., Tobin, M., Topp-Joergensen, S., Torr, N., Tran, M. T., Tsaregorodtsev, A., Tuning, N., Ukleja, A., Urquijo, P., Uwer, U., Vagnoni, V., Valenti, G., Vazquez Gomez, R., Vazquez Regueiro, P., Vecchi, S., Velthuis, J. J., Veltri, M., Vervink, K., Viaud, B., Videau, I., Vilasis-Cardona, X., Visniakov, J., Vollhardt, A., Voong, D., Vorobyev, A., Voss, H., Wacker, K., Wandernoth, S., Wang, J., Ward, D. R., Webber, A. D., Websdale, D., Whitehead, M., Wiedner, D., Wiggers, L., Wilkinson, G., Williams, M. P., Williams, M., Wilson, F. F., Wishahi, J., Witek, M., Witzeling, W., Wotton, S. A., Wyllie, K., Xie, Y., Xing, F., Xing, Z., Yang, Z., Young, R., Yushchenko, O., Zavertyaev, M., Zhang, L., Zhang, W. C., Zhang, Y., Zhelezov, A., Zhong, L., Zverev, E., and Zvyagin, A.

Subjects
Science & Technology, Physics, Nuclear, PHYSICS, MULTIDISCIPLINARY, Physics, Physical Sciences, MODES, CP VIOLATION, Astronomy & Astrophysics, Physics, Particles & Fields, Settore FIS/04 - Fisica Nucleare e Subnucleare, NO
Abstract

The first observation of the decay (B) over bar (0)(S) -> (DK)-K-0*(0) using pp data collected by the LHCb detector at a centre-of-mass energy of 7 TeV, corresponding to an integrated luminosity of 36 pb(-1), is reported. A signal of 34.4 +/- 6.8 events is obtained and the absence of signal is rejected with a statistical significance of more than nine standard deviations. The (B) over bar (0)(S) -> (DK)-K-0*(0) branching fraction is measured relative to that of (B) over bar (0) -> D-0 rho(0): B((B) over bar (0)(S)->(DK)-K-0*(0))/B((B) over bar (0)-> D-0 rho(0)) = 1.48+/-0.34+/-0.15+/-0.12, where the first uncertainty is statistical, the second systematic and the third is due to the uncertainty on the ratio of the B-0 and B-s(0) hadronisation fractions. (C) 2011 CERN. Published by Elsevier B.V. All rights reserved.

Published
2011

24. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

Author

Cozzi-Lepri, Alessandro, Phillips, Andrew N., D'Arminio Monforte, Antonella, Piersantelli, Nicoloò, Orani, Anna, Petrosillo, Nicola, Leoncini, Francesco, Scerbo, Antonio, Tundo, Paolo, Abrescia, Nicola, Montroni, M., Scalise, G., Costantini, Alessia, Del Prete, M. S., Tirelli, U., Nasti, G., Pastore, G., Ladisa, N., Perulli, L. M., Suter, F., Arici, C., Chiodo, F., Gritti, F. M., Colangeli, V., Fiorini, C., Guerra, L., Carosi, G., Cadeo, G. P., Castelli, F., Minardi, C., Vangi, D., Rizzardini, G., Migliorino, G., Manconi, P. E., Piano, P., Ferraro, T., Scerbo, A., Pizzigallo, E., Ricci, Fiammetta, Rinaldi, E., Pusterla, L., Carnevale, G., Galloni, D., Viganò, P., Mena, M., Ghinelli, F., Sighinolfi, L., Leoncini, F., Mazzotta, F., Ambu, S., Lo Caputo, S., Angarano, G., Grisorio, B., Ferrara, S., Grima, P., Tundo, P., Pagano, G., Piersantelli, N., Alessandrini, A., Piscopo, R., Toti, M., Chigiott, S., Soscia, F., Tacconi, L., Orani, A., Castaldo, G., Scasso, A., Vincenti, A., Scalzini, A., Alessi, F., Moroni, M., Lazzarin, A., Cargnel, A., Vigevani, G. M., Caggese, L., d’Arminio Monforte, A., Bongiovanni, M., Novati, R., Delfanti, F., Merli, S., Pastecchia, C., Moioli, C., Esposito, R., Mussini, C., Abrescia, N., Chirianni, A., Izzo, OMAR CARLO ENRICO, Piazza, M., De Marco, M., Montesarchio, V., Manzillo, E., Nappa, S., Colomba, A., Abbadessa, V., Prestileo, T., Mancuso, S., Filice, G., Minoli, L., Bruno, R., Maserati, R., Pauluzzi, S., Tosti, A., Alberici, F., Sisti, M., Menichetti, F., Smorfa, A., De Stefano, C., Lagala, A., Zauli, T., Ballardini, G., Bonazzi, L., Ursitti, M. A., Ciammarughi, R., Ortolani, P., Ortona, L., Dianzani, F., Antinori, A., Antonucci, G., D’Elia, S., Ippolito, G., Narciso, P., Petrosillo, N., Rezza, G., Vullo, V., De Luca, A., Del Forno, A., Capobianchi, M. R., Zaccarelli, M., De Longis, P., Ciardi, M., Girardi, E., D’Offizi, G., Noto, P., Pezzotti, P., Bugarini, R., Lichter, M., Mura, M. S., Mannazzu, M., Caramello, P., Caramello, A., Soranzo, M. L., Gennero, L., Sciandra, M., Salassa, B., Grossi, P. A., Basilico, C., Poggio, A., Bottari, G., Raise, E., Pasquinucci, S., De Lalla, F., Tositti, G., Resta, F., and Chimienti, A.

Subjects
Cyclopropanes, Adult, Male, medicine.medical_specialty, Efavirenz, Nevirapine, Settore MED/17 - Malattie Infettive, Adolescent, Antiretroviral Therapy, Pharmacology, Efficacy, Cohort Studies, chemistry.chemical_compound, Drug Therapy, Antiretroviral Therapy, Highly Active, Internal medicine, Oxazines, medicine, Humans, Immunology and Allergy, Highly Active, Viral, Sida, Aged, Acquired Immunodeficiency Syndrome, biology, Reverse-transcriptase inhibitor, business.industry, Middle Aged, biology.organism_classification, Confidence interval, Benzoxazines, CD4 Lymphocyte Count, Infectious Diseases, chemistry, Alkynes, Cohort, Combination, RNA, Viral, RNA, Drug Therapy, Combination, Female, business, Cohort study, medicine.drug
Abstract

This nonrandomized study compared the virologic and immunologic responses to potent regimens containing either efavirenz or nevirapine after considering potential systematic differences between patients receiving these drugs. Virologic failure was defined as the first of 2 consecutive measurements of virus load >500 human immunodeficiency virus RNA copies/mL. Of the 694 patients included in the analysis, 460 (66.3%) started nevirapine and 234 (33.7%) started efavirenz. The adjusted relative hazard of virologic failure for patients who started nevirapine, compared with those who started efavirenz, was 2.08 (95% confidence interval, 1.37-3.15; P=.0006). In addition, patients receiving efavirenz tended to recover 5 CD4 cells/microL more per quarter (P=.05). Although comparisons of drug efficacy in nonrandomized studies should be viewed with caution, no results from randomized controlled comparisons of these drugs are thought to be available. The findings of this study are in agreement with those of other observational studies.

Published
2002

33. A category of compositional domain-models for separable Stone spaces

Author

Alessi, F., Baldan, Paolo, Honsell, F., Alessi, F., Baldan, Paolo, and Honsell, F.

Abstract

In this paper we introduce SFPM, a category of SFP domains which provides very satisfactory domain-models, i.e. partializations, of separable Stone spaces (2-Stone spaces). More specifically, SFPM is a subcategory of SFPep, closed under direct limits as well as many constructors, such as lifting, sum, product and Plotkin powerdomain. SFPM is structurally well behaved, in the sense that the functor MAX, which associates to each object of SFPM the Stone space of its maximal elements, is compositional with respect to the constructors above, and omega-continuous. A correspondence can be established between these constructors over SFPM and appropriate constructors on Stone spaces, whereby SFP domain-models of Stone spaces defined as solutions of a vast class of recursive equations in 2-Stone, can be obtained simply by solving the corresponding equations in SFPM. Moreover any continuous function between two 2-Stone spaces can be extended to a continuous function between any two SFPM domain-models of the original spaces. The category SFPM does not include all the SFP's with a 2-Stone space of maximal elements (CSFP's). We show that the CSFP's can be characterized precisely as suitable retracts of SFPM objects. Then the results proved for SFPM easily extends to the wider category having CSFP's as objects. Using SFPM , we explain two classical partializations of the space of finitary hypersets (the hyperuniverse N-omega [Forti, Honsell, Lenisa]) based on SFP domains (see [Abramsky], [Mislove, Moss, Oles]). We also show that these two domains are not isomorphic, thus providing a negative answer to a problem raised in [Mislove, Moss,Oles].

Published
2000

34. Cause and effect relationship of drug adverse events: Our experience using protease inhibitors of HIV [Relazione di causalità delle reazioni avverse a farmaci: Un'esperienza nell'utilizzo degli inibitori della proteasi di HIV]

Author

Bonfanti, P, Valsecchi, L, Parazzini, F, Carradori, S, Pusterla, L, Fortuna, P, Timillero, L, Alessi, F, Ghiselli, G, Gabbuti, A, Ricci, E, Martinelli, C, Faggion, I, Landonio, S, Quirino, T, Bonfanti, P, Valsecchi, L, Parazzini, F, Carradori, S, Pusterla, L, Fortuna, P, Timillero, L, Alessi, F, Ghiselli, G, Gabbuti, A, Ricci, E, Martinelli, C, Faggion, I, Landonio, S, and Quirino, T

Abstract

Purpose: To establish the exact cause and effect relationship between protease inhibitors (PIs) and adverse events. Materials and Method: Prospective, cohort, multicenter study on HIV-positive patients who are beginning treatment with a PI. Causal relationships are evaluated using the RUCAM algorithm. Results: Since the beginning of the study 1207 patients have been enrolled. Average time of observation is 10.7 months. To date, 784 adverse events have been observed, distributed as follows: excluded 3.8%, improbable 18.5%, possible 41.3%, probable 30.1%, and highly probable 6.3%. Saquinavir shows a statistically significant difference in the rate of non-correlated events with respect to other groups. Conclusions: Over 20% of adverse events during PI treatment are shown to be non-correlated to these drugs. Saquinavir shows the highest rate of non-correlated events.

Published
2000

43. Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy

Author

Perno, Carlo Federico, Cozzi-Lepri, Alessandro, Balotta, Claudia, Forbici, Federica, Violin, Michela, Bertoli, Ada, Facchi, Guido, Pezzotti, Patrizio, Angarano, Gioacchino, Arici, Claudio, Narciso, Pasquale, Orani, Anna, Raise, Enzo, Scalzini, Alfredo, Poggio, Antonio, Ippolito, Giuseppe, Moroni, Mauro, Monforte, Antonella d'Arminio, Montroni, M, Scalise, G, Costantini, A, Del Prete, MS, Tirelli, U, Nasti, G, Pastore, G, Perulli, LM, Suter, F, Arici, C, Chiodo, F, Gritti, FM, Colangeli, V, Fiorini, C, Guerra, L, Carosi, G, Cadeo, GP, Castelli, F, Minardi, C, Vangi, D, Rizzardini, G, Migliorino, G, Manconi, PE, Piano, P, Ferraro, T, Cosco, L, Pizzigallo, E, Ricci, F, Vigevani, GM, Pusterla, L, Carnevale, G, Pan, A, Viganò, P, Mena, M, Ghinelli, F, Sighinolfi, L, Leoncini, F, Mazzotta, F, Ambu, S, Lo Caputo, S, Angarano, G, Grisorio, B, Ferrara, S, Grima, P, Tundo, P, Pagano, G, Piersantelli, N, Alessandrini, A., Piscopo, R., Toti, M, Chigiotti, Soscia, F, Tacconi, L, Orani, A, Castaldo, G, Scasso, A, Vincenti, A, Scalzini, A, Alessi, F, Moroni, M, Lazzarin, A, Cargnel, A, Milazzo, F, Caggese, L, Monforte, A d'Arminio, Melzi, S, Delfanti, F, Carini, B, Adriani, B, Garavaglia, S, Moioli, C, Esposito, R, Mussini, C, Abrescia, N, Chirianni, A, Perrella, O, Piazza, M, De Marco, M, Montesarchio, V, Manzillo, E, Nappa, S, Cadrobbi, P, Scaggiante, R, Colomba, A, Abbadesse, V, Prestileo, T, Mancuso, S, Filice, G, Minoli, L, Savino, FA Patruno, Maserati, R, Pauluzzi, S, Baldelli, F, Petrelli, E, Ciotti, A, Alberici, F, Sisti, M, Menichetti, F, Smorfa, A, De Stefano, C, La Gala, A, Zauli, T, Ballardini, G, Bonazzi, L, Ursitti, MA, Ciammarughi, R, Giordani, S, Ortona, L, Dianzani, F, Ippolito, G, Antinori, A, Antonucci, G, D'Elia, S, Narciso, P, Petrosillo, N, Vullo, V, De Luca, A, Del Forno, A, Zaccarelli, M, De Longis, P, Ciardi, M, D'Offizi, G, Palmieri, F, Lichter, M, Capobianchi, MR, Girardi, E, Pezzotti, P, Rezza, G, Mura, MS, Mannazzu, M, Caramello, P, Sinicco, A, Soranzo, ML, Quaglia, S, Sciandra, M, Salassa, B, Torre, D, Basilico, C, Poggio, A, Bottari, G, Raise, E, Pasquinucci, S, De Lalla, F, Tositti, G, Resta, F, Chimienti, A, Lepri, A Cozzi, and Phillips, AN

Published
2001
Full Text
View/download PDF

44. The human adult skeletal muscle transcriptional profile reconstructed by a novel computational approach.

Author

Bortoluzzi, S, d'Alessi, F, Romualdi, C, and Danieli, G A

Abstract

By applying a novel software tool, information on 4080 UniGene clusters was retrieved from three adult human skeletal muscle cDNA libraries, which were selected for being neither normalized nor subtracted. Reconstruction of a transcriptional profile of the corresponding tissue was attempted by a computational approach, classifying each transcript according to its level of expression. About 25% of the transcripts accounted for about 80% of the detected transcriptional activity, whereas most genes showed a low level of expression. This in silico transcriptional profile was then compared with data obtained by a SAGE study. A fairly good agreement between the two methods was observed. About 400 genes, highly expressed in skeletal muscle or putatively skeletal muscle-specific, may represent the minimal set of genes needed to determine the tissue specificity. These genes could be used as a convenient reference to monitor major changes in the transcriptional profile of adult human skeletal muscle in response to different physiological or pathological conditions, thus providing a framework for designing DNA microarrays and initiating biological studies.

Published
2000

45. Solutions of Functorial and Non-Functorial Metric Domain Equations1 1Work partially supported by ECC Science project MASK and by MURST 40% grants

Author

Alessi, F., Baldan, P., Bellè, G., and Rutten, J.J.M.M.

Subjects
Mathematics::Category Theory, Theoretical Computer Science, Computer Science(all)
Abstract

A new method for solving domain equations in categories of metric spaces is studied. The categories CMS≈ and KMS≈ are introduced, having complete and compact metric spaces as objects and ɛ-adjoint pairs as arrows. The existence and uniqueness of fixed points for certain endofunctors on these categories is established. The classes of complete and compact metric spaces are considered as pseudo-metric spaces, and it is shown how to solve domain equations in a non-categorical framework.

Full Text
View/download PDF

46. A comprehensive, high-resolution genomic transcript map of human skeletal muscle.

Author

Bortoluzzi, S, Rampoldi, L, Simionati, B, Zimbello, R, Barbon, A, d'Alessi, F, Tiso, N, Pallavicini, A, Toppo, S, Cannata, N, Valle, G, Lanfranchi, G, and Danieli, G A

Abstract

We present the Human Muscle Gene Map (HMGM), the first comprehensive and updated high-resolution expression map of human skeletal muscle. The 1078 entries of the map were obtained by merging data retrieved from UniGene with the RH mapping information on 46 novel muscle transcripts, which showed no similarity to any known sequence. In the map, distances are expressed in megabase pairs. About one-quarter of the map entries represents putative novel genes. Genes known to be specifically expressed in muscle account for <4% of the total. The genomic distribution of the map entries confirmed the previous finding that muscle genes are selectively concentrated in chromosomes 17, 19, and X. Five chromosomal regions are suspected to have a significant excess of muscle genes. Present data support the hypothesis that the biochemical and functional properties of differentiated muscle cells may result from the transcription of a very limited number of muscle-specific genes along with the activity of a large number of genes, shared with other tissues, but showing different levels of expression in muscle. [The sequence data described in this paper have been submitted to the EMBL data library under accession nos. F23198-F23242.]

Published
1998
Full Text
View/download PDF

49. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study

Author

Silvia Carradori, Canio Martinelli, Alessi F, Ivano Faggion, Laura Valsecchi, Paolo Bonfanti, Simona Landonio, Tiziana Quirino, Fortuna P, Andrea Gabbuti, Luigi Pusterla, Fabio Parazzini, Ghiselli G, Di Cintio E, Timillero L, Bonfanti, P, Valsecchi, L, Parazzini, F, Carradori, S, Pusterla, L, Fortuna, P, Timillero, L, Alessi, F, Ghiselli, G, Gabbuti, A, Di Cintio, E, Martinelli, C, Faggion, I, Landonio, S, and Quirino, T

Subjects
medicine.medical_specialty, viruses, Gastroenterology, Pharmacotherapy, immune system diseases, Indinavir, Internal medicine, medicine, Pharmacology (medical), Prospective cohort study, Adverse effect, Surveillance, business.industry, Incidence (epidemiology), virus diseases, Adverse reaction, biochemical phenomena, metabolism, and nutrition, Antiretroviral therapy, Discontinuation, Infectious Diseases, Nelfinavir, Protease inhibitor, Immunology, Ritonavir, business, Saquinavir, medicine.drug
Abstract

Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued because of adverse events (AE) and to evaluate the incidence rate of adverse reactions during PI treatment. Design: A prospective cohort, multicenter study on HIV-positive patients starting treatment with at least one PI. Setting: Ten departments of infectious diseases in Northern Italy. Patients: A total of 1207 patients who started PI therapy in September 1997 and were consecutively observed up to April 1999. Main Outcome Measures: Adverse reactions following initiation of PI therapy, and time to therapy discontinuation due to AE. Results: During the study period, 35.9% patients presented adverse reactions of any grade, whereas 9.7% presented at least one serious AE. After 12 months of treatment, the percentage of patients who had interrupted treatment was 36% of ritonavir-treated patients, 14.2% of those treated with indinavir, 13.6% of ritonavir-saquinavir hard gel capsules (HGC)-treated patients, and 8.5% and 2.1%, respectively, for those treated with nelfinavir and saquinavir HGC. Women and patients with hepatitis experienced a significantly greater number of adverse events compared with other categories. Gastrointestinal events were more frequently observed in patients treated with either ritonavir alone or in combination with saquinavir HGC, as well as in patients receiving nelfinavir, although in this group serious events were rare. Here again, neurologic, metabolic, and hepatic toxicity occurred more frequently in ritonavir and ritonavirsaquinavir HGC treated patients. Allergic reactions were more often observed in patients receiving nelfinavir. Indinavir-treated patients presented the highest incidence of renal toxicity. Conclusion: Ritonavir is the drug associated with the largest number of reactions, which appear during the first few months of treatment. Saquinavir HGC and nelfinavir are the best tolerated drugs in a clinical setting.

50. Cause and effect relationship of drug adverse events: Our experience using protease inhibitors of HIV | Relazione di causalità delle reazioni avverse a farmaci: Un'esperienza nell'utilizzo degli inibitori della proteasi di HIV

Author

Bonfanti, P., Valsecchi, L., fabio parazzini, Carradori, S., Pusterla, L., Fortuna, P., Timillero, L., Alessi, F., Ghiselli, G., Gabbuti, A., Ricci, E., Martinelli, C., Faggion, I., Landonio, S., Quirino, T., Bonfanti, P, Valsecchi, L, Parazzini, F, Carradori, S, Pusterla, L, Fortuna, P, Timillero, L, Alessi, F, Ghiselli, G, Gabbuti, A, Ricci, E, Martinelli, C, Faggion, I, Landonio, S, and Quirino, T

Subjects
Pharmacovigilance, HIV, Cohort study
Abstract

Purpose: To establish the exact cause and effect relationship between protease inhibitors (PIs) and adverse events. Materials and Method: Prospective, cohort, multicenter study on HIV-positive patients who are beginning treatment with a PI. Causal relationships are evaluated using the RUCAM algorithm. Results: Since the beginning of the study 1207 patients have been enrolled. Average time of observation is 10.7 months. To date, 784 adverse events have been observed, distributed as follows: excluded 3.8%, improbable 18.5%, possible 41.3%, probable 30.1%, and highly probable 6.3%. Saquinavir shows a statistically significant difference in the rate of non-correlated events with respect to other groups. Conclusions: Over 20% of adverse events during PI treatment are shown to be non-correlated to these drugs. Saquinavir shows the highest rate of non-correlated events.

Catalog

Books, media, physical & digital resources
See catalog results